Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-cell immunopathology of recurrent acute generalized exanthematous pustulosis associated with vancomycin.

The journal of allergy and clinical immunology. Global·2025
Same author

Extradigital Symplastic Glomus Tumor and Review of the Literature.

The American Journal of dermatopathology·2024
Same author

An erythematous nodule on the nose.

International journal of dermatology·2024
Same author

Acral keratosis with eosinophilic dermal deposits: A rare subtype of colloid milium.

Journal of cutaneous pathology·2022
Same author

Cutaneous dermatomycosis with concurrent <i>Paecilomyces lilacinus</i> and <i>Candida guilliermondii</i> in a patient with longstanding diabetes.

JAAD case reports·2021
Same author

Case Report: Infantile Urticaria as a Herald of Neonatal Onset Multisystem Inflammatory Disease With a Novel Mutation in NLRP3.

Frontiers in immunology·2021
Same journal

Comparative Alopecia Outcomes After Copper and Hormonal Intrauterine Device Placement: A TriNetX Database Retrospective Cohort Study.

Journal of the American Academy of Dermatology·2026
Same journal

Uncovering a Dual Th17/Type 2 Transcriptomic Endotype in Psoriasis.

Journal of the American Academy of Dermatology·2026
Same journal

Dermatologic conditions associated with HIV among US adults across different racial and ethnic groups: A retrospective cohort study using TriNetX.

Journal of the American Academy of Dermatology·2026
Same journal

Ethical Considerations in Same-Day Surgical Treatment of a High-Risk, Poorly Differentiated Squamous Cell Carcinoma.

Journal of the American Academy of Dermatology·2026
Same journal

The Ethics of the Handshake in Dermatology.

Journal of the American Academy of Dermatology·2026
Same journal

Dermatology images: Hidradenitis suppurativa.

Journal of the American Academy of Dermatology·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

Leflunomide in dermatology.

Alan S Boyd1

  • 1Departments of Medicine (Dermatology) and Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, USA. alan.boyd@Vanderbilt.edu

Journal of the American Academy of Dermatology
|October 4, 2011
PubMed
Summary
This summary is machine-generated.

Leflunomide is an effective oral medication for rheumatoid and psoriatic arthritis. It works by inhibiting an enzyme crucial for pyrimidine production and reducing tumor necrosis factor-alfa activity, benefiting various skin and joint conditions.

More Related Videos

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

Related Experiment Videos

Last Updated: May 28, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

Area of Science:

  • Immunology
  • Rheumatology
  • Dermatology

Background:

  • Rheumatoid arthritis and psoriatic arthritis are chronic inflammatory conditions.
  • Leflunomide is an established oral disease-modifying antirheumatic drug (DMARD).

Purpose of the Study:

  • To summarize the mechanism of action and therapeutic applications of leflunomide.
  • To highlight its efficacy in rheumatologic and dermatologic conditions.

Main Methods:

  • Review of leflunomide's pharmacological properties.
  • Analysis of clinical data regarding its use in arthritis and psoriasis.

Main Results:

  • Leflunomide inhibits dihydroorotate dehydrogenase, impacting pyrimidine synthesis.
  • It also down-regulates tumor necrosis factor-alfa activity.
  • Clinical studies show leflunomide is useful for rheumatoid arthritis, psoriatic arthritis, and cutaneous psoriasis.

Conclusions:

  • Leflunomide is a valuable therapeutic option for patients with rheumatoid and psoriatic arthritis.
  • Its mechanism of action provides benefits in managing inflammatory dermatologic conditions like psoriasis.